Please assess the completion status of the following clinical trial:

Trial Title: Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* Moderate or severe risk of prematurity~* Mono-fetal pregnancy~* And a term of pregnancy \> = 24 weeks and \<34 weeks of gestation at diagnosis~* subjects affiliated with an appropriate social security system~* written signed informed consent form~Exclusion Criteria:~* Age \< 18 years old~* Major under trusteeship or curatorship~* Maternal refusal and / or Incapacity to understand the benefits and potential risks of the protocol and to sign an informed consent form.~* A sonographic cervix ≥ 20 mm~* Mothers WITH:~  * A Body mass index less than 18 kg/m2 and greater than 40 kg/m2 before pregnancy~ * Type I, II diabetes~ * Epileptic disorders~ * A history of asthma~ * A hemorrhagic pathology~ * Maternal infection (HIV, hepatitis B and C) other than chorioamnionitis~* Patients in labour treated with magnesium sulphate~* Multiple pregnancy~* A known allergy/ hypersensitivity to N-acetylcysteine~* Fetal pathology other than intrauterine growth retardation (such as: karyotype abnormality, malformation, intrauterine growth retardation \<10th percentile)~* Current high doses of antioxidants treatments (vitamin supplements, ...)~* Patient with proven pre-eclampsia~* Patient with heart failure~* Patient with nephropathy~* Patient with medically known lactose intolerance~* Patient not affiliated with an appropriate social security system

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (NAC) (Type: EXPERIMENTAL): High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age.
- Placebo (Type: PLACEBO_COMPARATOR): High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age.

Based on this trial design, predict the completion outcome and termination type (if applicable).